Open access
Aug 2026
Clostridium Butyricum and butyrate enhance PD-1 inhibitor therapy in non-small cell lung cancer by regulating the HDAC1/ID2/IL-12R pathway
Highlights • NaB and C. butyricum enhance PD-1 inhibitor activity in NSCLC.• NaB and C. butyricum offer an alternative therapeutic mechanism via HDAC1 inhibition.• NaB cooperates with the PD-1 inhibitors depending on CD8+ T cells in NSCLC.
Zhuo Chen, Meng-Lei Wang, Zhuo-Wen Zhang et al.
· Translational Oncology · 1 citation